Bioma achieves this by delivering good bacteria to the gut, hence balancing the microbiome. Nourishing prebiotics to ...

Andrew Taylor announced on April 22 as new EVP Food & Beverages, joining the company no later than September 1, 2025. 2025 outlook maintained: 5-8% organic sales growth (6-9% excluding the exit from ...

Martin Olin, Chief Executive Officer at Swarm Oncology will deliver the presentation on Novel Immunotherapy for Solid Cancers. Title: Novel Immunotherapy for Solid Cancers Presenter: Martin Olin ...

Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first ...

The first quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET. A webcast of the live call may be ...

Leiden, the Netherlands, May 8, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary unaudited financial report for the three ...

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for ...

In light of the preliminary Q1 results and the integration of the Danish-based freight forwarder DTK, we are updating our full-year outlook for 2025 as follows: Adj. EBIT of DKK 560 - 630 million ...

Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika’s website, www.anika.com. An archive of the presentation will also be available on the website.

About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million — Conference call scheduled for toda ...